AOP Orphan, a European pioneer in the field of rare diseases, is expanding its sales area for the preparation of Thromboreductin® to include the Russian market. The drug is an innovative treatment option for patients afflicted by Essential Thrombocythemia (ET), a rare but serious bone marrow disease.
The drug is currently available in core European markets including Austria, Hungary, Switzerland, Czech Republic and Poland as well as Turkey, Israel, Kazakhstan and Russia.
ET is characterised by a significantly elevated blood platelet count increasing the risk of suffering a blood clot or bleeding. Thromboreductin® (active ingredient anagrelide) lowers the blood platelet count and reduces the risk of complications. This drug is not associated with a possible risk of leukemogenesis as is currently the case with cytostatic agents. Treatment with this drug, if successful, could help patients have an almost normal life expectancy.
AOP Orphan is a pharmaceutical company engaged in researching, developing, producing and distributing innovative drugs and administration methods. It is a pioneer in the field of orphan diseases and focuses on the areas of haematology, oncology, cardiology, pulmonology, neurology and psychiatry and metabolic diseases.
The Austrian company has a turnover of more than EUR 60 million. It has branch offices situated in core markets within the EU, Switzerland and the Middle East and its international markets are handled and operated by long-term close partners. The company has an export ratio of around 70 percent and employs over 140 people. It has twelve locations.
Source: AOP Orphan
Image Credit: AOP Orphan
